In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...

An “America first” drug sourcing order signed Thursday is the latest in a series of attempts by President Donald Trump to bend the biopharma industry to his will in an effort to keep campaign promises...

Recommendations from a task force assembled by Joe Biden and Sen. Bernie Sanders (I-Vt.) include several healthcare policies favored by Democrats, like Medicare drug price negotiation, but stop short of Medicare for All. The bulk...

As the COVID-19 pandemic makes clear the need for innovative therapies to treat infectious diseases, a trio of Republicans on the House Ways and Means Committee introduced a series of bills offering tax benefits for...

President Donald Trump will sign executive orders this week on drug pricing, bringing manufacturing back to the U.S., and immigration, White House Chief of Staff Mark Meadows said Monday in a television interview on Fox...

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...

While VCs have broadly applauded the U.K. government for launching the £250 million Future Fund to provide financial aid to private companies hit by the pandemic, the size and structure of the fund makes it...

As the U.S. seeks to secure its supply chain following global disruptions from the COVID-19 pandemic, two Republican lawmakers are backing legislation that would enact a tax incentive to encourage manufacturers to keep production domestic....

With its series A funds deployed to acquire three rare disease programs, Rallybio has raised a $145 million series B led by Pivotal bioVenture Partners to bring the first of those candidates into the clinic...

The BioIndustry Association is calling on the U.K. government to advance payments from its R&D tax credit system to unlock five times the capital being offered under a new £1 billion ($1.2 billion) plan to...